RecruitingPhase 2interventionalRules rewrite

Phase 2: testing HS-20137 for Moderate-to-severe Plaque Psoriasis

Q: Is NCT07879885 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

Q: What phase is NCT07879885?

Phase 2. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Q: Can PlainTrials tell me if I qualify for NCT07879885?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

This study wants to measure the safety and how well it works of HS-20137 in the treatment of participants with moderate-to-severe plaque psoriasis

Official registry: https://clinicaltrials.gov/study/NCT07879885 · Hansoh BioMedical R&D Company · enrollment listed as 390

What this phase means

Phase 2: researchers already know a roughly safe dose (from phase 1). This stage asks whether the treatment actually helps the condition, and watches side effects more closely.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are HS-20137. The registry lists allocation as na. This study wants to measure the safety and how well it works of HS-20137 in the treatment of participants with moderate-to-severe plaque psoriasis

They plan to enroll about 390 people at Beijing. Taking part typically means an infusion or injection of a biologic plus check-ins.

Official title (unrewritten)

An Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of HS-20137, an Anti-IL-23 Monoclonal Antibody, in Participants With Moderate-to-severe Plaque Psoriasis

Interventions: HS-20137

Primary outcome (registry wording): Number of Participants with Adverse Events

Who it is for (from inclusion criteria)

Ages 18 Years to any
Adults aged 18 and above, male or female;
Diagnosed plaque psoriasis for at least 6 months before randomization, with or without psoriatic arthritis;
During screening and randomization, the severity of plaque psoriasis was moderate to severe, and the following conditions should be met: a) BSA≥3%; b) PASI≥3;

Who the registry excludes

History of an allergic reaction following prior use of a biologic agent, allergy to known drug components, or a history of severe food or drug allergy;
Use of the following drugs before the first dose:
Use of topical treatment drugs that affect the evaluation of psoriasis within 2 weeks before the first dose;
1 weeks before the first administration, Use of phototherapy, traditional systemic therapy drugs, small molecule targeted drugs that may affect the evaluation of psoriasis;

Contact

No central phone on the registry card. Use the official listing to reach a site.

Sites listed on ClinicalTrials.gov

1 listed

China-Japan Friendship Hospital — Beijing, Beijng, China (recruiting)

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseHamburg

PsoBest - The German Psoriasis Registry

Treatment of moderate to severe Psoriasis (Pso) and Psoriasis-Arthritis (PsA) is largely confined to systemic therapy in Germany. Systemic therapy includes conventional systemic therapy (e.g.

NCT01848028 · Official ClinicalTrials.gov record · Universitätsklinikum Hamburg-Eppendorf

RecruitingNot a traditional drug phaseBerlin, State of Berlin

Not a traditional drug phase: testing Glucocorticoid treatment for Osteoporosis

Glucocorticoids remain to be among the most important and most frequently used anti-inflammatory and immunosuppressive or immune-modulatory acting drugs to treat rheumatic (and other) diseases. Unfortunately, glucocorticoids also exert undesired effects, especially if higher dosages have to be given over longer periods of time.

NCT02719314 · Official ClinicalTrials.gov record · Prof Dr Frank Buttgereit

RecruitingPhase 3Ciudad Autonoma de Buenos Aires, Buenos Aires

Phase 3: testing Deucravacitinib for Plaque Psoriasis

The purpose of this pediatric study is to measure the drug levels, how well it works and safety of Deucravacitinib in children and adolescent participants aged 4 to \<18 years with moderate to severe plaque psoriasis. This study includes two cohorts; Cohort 1 (age 12 to \<18 years) and Cohort 2 (age 4 to \<12 years), with two parts; for each cohort.

NCT04772079 · Official ClinicalTrials.gov record · Bristol-Myers Squibb

FAQ about this NCT record

Is NCT07879885 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07879885?

Phase 2. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07879885?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary